Recombinant SARS-CoV-2 S1 Subunit Protein (RBD) with C-terminal Mouse IgG Fc Tag

Binding assay, glycosylation analysis, biotin/dye/bead conjugation, other functional assays.

C-terminal mouse IgG Fc-tag

-20°C

Recombinant SARS-CoV-2 S1 subunit protein (RBD) with C-terminal mouse IgG Fc-tag, derived from the transfected human HEK293 cells. Datasheet

12352202

Arg319-Phe541

Protein G affinity purification

Figure 1. Deglycosylation of purified recombinant proteins. Purified proteins were untreated (Lane 2) or treated with deglycosylation under native (Lane 3) or reducing (Lane 4) conditions. Deglycosylation treatment resulted in a mobility shift of the protein to produce one major band at the expected size (ˆ¼50 kDa), thus indicating that the untreated recombinant protein (Lane 2, ˆ¼65 kDa) was glycosylated.Lane 1: Protein standard ladder (kDa) Lane 2: Untreated protein (ˆ¼65 kDa, red arrow) under reducing conditions.Lane 3: Treated protein (ˆ¼50 kDa, green arrow) with deglycosylation enzymes under native conditions.Lane 4: Treated protein (ˆ¼50 kDa, green arrow) with deglycosylation enzymes under reducing conditions.

The human ACE2 protein product (Catalog #230-30165) was coated in 96-well plate and incubated with the serial diluted recombinant S1/RBD-Fc protein (Catalog #230-30166). The bound S1/RBD-Fc (Catalog #230-30166) was detected by HRP-conjugated anti-mouse IgG antibody using ELISA. The calculated EC50 is 9.85-13.46 ng/mL.